Every tradition recorded plant medicines; isolating and testing a compound turned a few records into drugs
This course follows written records of plant medicine from Mesopotamian clay tablets to a 44,691-record database, across eleven regions. It then traces how a handful of records became purified, characterized drugs, and why most did not.
Twelve plant records in this course led to isolated compounds, and three of those compounds led on to new drugs
Data table: the links shown
| From | To | Date or note |
|---|---|---|
| Opium poppy | Morphine | Sertürner: reported 1805, full account 1817 |
| Cinchona bark | Quinine | Pelletier and Caventou, 1820 |
| Foxglove (Digitalis) | Digoxin | Smith, from Digitalis lanata, 1930 |
| Calabar bean | Physostigmine | First isolated 1864 |
| Rauwolfia serpentina | Reserpine | – |
| Artemisia annua | Artemisinin | Isolated November 1972 |
| Catharanthus roseus | Vinblastine and vincristine | Noble and Beer, 1950s |
| Curare | Tubocurarine | King, 1935 |
| Jaborandi leaves | Pilocarpine | – |
| Mayapple (podophyllin) | Podophyllotoxin | – |
| Willow bark | Salicin | Leroux, 1829: about 30 g from 1.5 kg of bark |
| Galega officinalis | Guanidine | Shown in 1918 to lower blood glucose |
| Salicin | Acetylsalicylic acid | Hoffmann, August 10, 1897 |
| Podophyllotoxin | Etoposide | Podophyllotoxin derivative; inhibits topoisomerase II |
| Guanidine | Metformin | Sterne, 1957 |
You will learn
- Where and when the main medical records of eleven regions were written, with disputed dates shown as ranges.
- Why most historical remedies cannot be reconstructed from the text alone.
- How morphine, quinine, aspirin, artemisinin and other drugs moved from a record to a characterized molecule.
- How to read Newman and Cragg's statistics on natural-product drugs without overreading them.
- Which access-and-benefit-sharing rules now govern traditional knowledge.
Medical records survive from sixteen places on five continents, and the oldest dated writing is younger than the knowledge it records
Text version of the atlas key
- Mesopotamia: medical tablet from Nippur with prescriptions, c. 2200 BCE; Nineveh Medical Encyclopaedia, 7th century BCE, 50 tablets.
- Egypt: Ebers Papyrus, end of the 16th century BCE, 879 texts.
- Greece: Hippocratic Corpus, some 60 texts; Theophrastus (c. 371–287 BCE).
- Rome: Dioscorides, De materia medica, about 77 CE, nearly 600 plants.
- Persia: Ibn Sīnā's Canon of Medicine, begun about 1012; scholarship only.
- India: Charaka and Sushruta compendia; Rauwolfia research leading to reserpine, 1952.
- China: from 365 medicinals (Eastern Han) to 1,892 (Bencao Gangmu, 1578–1596).
- Japan: Ishinpō, 984; 148 Kampo formulas reimbursed today.
- Europe: willow, foxglove and poppy; morphine isolated 1805–1817.
- West Africa: Calabar bean; physostigmine isolated 1864.
- Madagascar: periwinkle; vinblastine and vincristine, 1950s.
- Southern Africa: Pelargonium and Hoodia benefit-sharing cases.
- North America: 44,691 recorded plant uses; mayapple and etoposide.
- Andes: cinchona bark, c. 1630; quinine, 1820.
- South America: curare; tubocurarine, 1935.
- Brazil: jaborandi; pilocarpine, 1875.
Explanation, details and sources
Shading gives the date of the oldest written record cited in this course. Oral knowledge is older than its first written record, which in Africa and the Americas was often made by outside observers.
Written records span four millennia, while isolated plant drugs cluster in the last two centuries
Showing all 65 dated steps.
| When | Region | Kind | What happened | Source |
|---|---|---|---|---|
| c. 2200 BCE | Mesopotamia | Historical record | Clay medical tablet with prescriptions from Nippur, dated c. 2200 BCE by the museum (CBS 14221). | Penn Museum, CBS 14221 |
| end of the 16th century BCE | Egypt | Historical record | Ebers Papyrus: 879 texts in 110 columns on nine areas of medicine; 70–80% of its ingredients are still unidentified. | Leipzig University Library |
| 8th–7th century BCE | Mesopotamia | Historical record | BAM 1, a large three-column tablet that Geller calls an apothecary's handbook of plant drugs and their uses. | Geller 2020 |
| 7th century BCE | Mesopotamia | Historical record | Nineveh Medical Encyclopaedia in the library of Ashurbanipal: 12 sections from head to foot, 50 tablets, more than 10,000 lines. | British Museum; Simko 2021 |
| date disputed | India | Historical record | Sushruta-samhita, on surgery and pharmacology: dated c. 6th century BCE by Britannica, about two millennia ago by the Suśruta Project. | Britannica; Suśruta Project |
| late 5th–4th century BCE | Greece and Rome | Historical record | Hippocratic Corpus: some 60 texts by several authors, mostly late 5th and 4th century BCE. | Totelin 2015 |
| c. 371–287 BCE | Greece and Rome | Historical record | Theophrastus, Aristotle's pupil: Inquiry into Plants (9 books) and Growth of Plants (6 books). | Britannica |
| 2nd c. BCE–2nd c. CE | India | Historical record | Charaka lived between the 2nd century BCE and the 2nd century CE; the Charaka-samhita's present form dates from about the 1st century CE. | Britannica |
| 23–79 | Greece and Rome | Historical record | Pliny the Elder (23–79 CE): Natural History in 37 books. | Britannica |
| Eastern Han, 25–220 CE | China | Historical record | Shennong Bencao Jing, compiled in the Eastern Han (25–220 CE): 365 medicinals in three grades. | Zhao et al. 2018 |
| c. 77 CE | Greece and Rome | Historical record | Dioscorides, De materia medica, about 77 CE: five books, nearly 600 plants, about 1,000 simple drugs. | Britannica |
| c. 129–216 | Greece and Rome | Historical record | Galen of Pergamum (129–c. 216): dominant in European medicine until the mid-17th century. | Britannica |
| c. 317–420 CE | China | Historical record | Ge Hong's Handbook of Prescriptions for Emergencies first records qinghao for periodic fevers. | Tu 2015 |
| 420–589 CE | China | Historical record | Tao Hongjing annotates the classic and adds 365 entries: 730 medicinals. | Zhao et al. 2018 |
| early 6th century | Greece and Rome | Historical record | Vienna Dioscurides, made for Juliana Anicia early in the 6th century; Memory of the World, 1997. | Austrian Commission for UNESCO |
| 562 CE | Japan | Historical record | Chinese medical books on herbal drugs and acupuncture arrive from Wu. | Kobayashi et al. 2010 |
| 659 CE | China | Historical record | Xin Xiu Bencao (659), commissioned by the Tang government: 850 medicinals; China's earliest national pharmacopoeia. | Zhao et al. 2018 |
| c. 854/865–925 | Persia | Historical record | al-Rāzī (Rhazes, c. 854/865–925): al-Ḥāwī, used in European curricula into the 14th century. | Edriss et al. 2017; Compier 2012 |
| 984 CE | Japan | Historical record | Tamba Yasuyori presents the Ishinpō, the oldest extant medical book in Japan, to the emperor. | Kobayashi et al. 2010 |
| c. 1012 | Persia | Historical record | Ibn Sīnā begins the Canon of Medicine about 1012; Book II covers simple drugs. | Nasser et al. 2009 |
| 1108 | China | Historical record | Zheng Lei Bencao (1108): 1,746 medicinals; the only bencao text from the Song or earlier to survive intact. | Zhao et al. 2018 |
| 12th century | Persia | Historical record | Gerard of Cremona (1114–1187) translates the Canon into Latin in Toledo. | Arráez-Aybar et al. 2015 |
| 16th century | South America | Historical record | Explorers describe South American arrow poisons (curares). | Bowman 2006 |
| 1578–1596 | China | Historical record | Bencao Gangmu by Li Shizhen: 1,892 drugs, 11,096 prescriptions; completed 1578, printed 1593 (UNESCO) or 1596 (Zhao et al.). | UNESCO MoW; Zhao et al. 2018 |
| c. 1630 | South America | Historical record | Jesuit missionaries use cinchona bark against fevers; a legend credits earlier Indigenous use. | Achan et al. 2011 |
| 1763 | Europe | Historical record | Edward Stone reports willow bark against agues (fevers) to the Royal Society. | Stone 1763; Wood 2015 |
| 1785 | Europe | Historical record | William Withering publishes An Account of the Foxglove. | Khandelwal et al. 2024 |
| 1805–1817 | Europe | Isolation or structure | Sertürner isolates morphine, the first alkaloid isolated from any plant (reported 1805; full account 1817). | Krishnamurti and Rao 2016 |
| 1820 | North America | Historical record | Mayapple enters the first U.S. Pharmacopoeia (1820) as a cathartic. | Singh et al. 2022 |
| 1820 | South America | Isolation or structure | Pelletier and Caventou isolate and name quinine; purified quinine replaces the bark. | Achan et al. 2011 |
| 1829 | Europe | Isolation or structure | Leroux purifies about 30 g of salicin from 1.5 kg of willow bark. | Wood 2015 |
| 1846–1863 | Africa | Historical record | Missionaries in Old Calabar document the ordeal bean (1846); Christison tests it (1855); Argyll Robertson shows it constricts the pupil (1863). | Proudfoot 2006 |
| 1864 | Africa | Isolation or structure | Physostigmine isolated from the Calabar bean; its structure was known by 1923. | Ramsay and Tipton 2017 |
| 1873 | South America | Historical record | Symphronio Coutinho takes jaborandi leaves to Europe. | Holmstedt et al. 1979 |
| 1875 | South America | Isolation or structure | Hardy and Gerrard independently discover pilocarpine; Weber introduces it as an eye drug in 1876. | Holmstedt et al. 1979 |
| 1897 | Europe | Clinical use or approval | Bayer chemists make pure acetylsalicylic acid (aspirin), August 1897. | Wood 2015 |
| 1918 | Europe | Isolation or structure | Guanidine, abundant in goat's rue (Galega officinalis), is shown to lower blood glucose. | Bailey 2017 |
| 1930 | Europe | Isolation or structure | Sydney Smith isolates digoxin from woolly foxglove (Digitalis lanata). | Smith 1930 |
| 1931 | India | Clinical use or approval | Sen and Bose report Rauwolfia serpentina root for insanity and high blood pressure. | Roy 2018 |
| 1932 | India | Isolation or structure | Siddiqui and Siddiqui publish the ajmaline series of Rauwolfia alkaloids. | Roy 2018 |
| 1935 | South America | Isolation or structure | King isolates tubocurarine from curare. | King 1935 |
| after 1943 | South America | Clinical use or approval | Neuromuscular blockers become established as muscle relaxants in surgical anaesthesia after 1943. | Bowman 2006 |
| 1949 | India | Clinical use or approval | Vakil's British Heart Journal paper on Rauwolfia in hypertension. | Roy 2018 |
| 1950s | Africa | Isolation or structure | Testing a reputed antidiabetic use of Madagascar periwinkle, Noble and Beer find anticancer alkaloids: vinblastine and vincristine. | Noble 1990; Talib et al. 2022 |
| 1952 | India | Isolation or structure | Reserpine isolated in pure crystalline form by Müller, Schlittler and Bein at CIBA. | Roy 2018 |
| 1957 | Europe | Clinical use or approval | Jean Sterne reports metformin for diabetes; U.S. approval follows on March 3, 1995. | Bailey 2017; Drugs@FDA, NDA 020357 |
| 1967 | Japan | Law, policy or agreement | Kampo formulas first covered by National Health Insurance; coverage expanded from 1976. | Kwon et al. 2026 |
| 1971 | China | Isolation or structure | Sample 191, the neutral portion of an ether extract of qinghao, is fully effective in rodent malaria (October 4, 1971). | Tu 2015 |
| 1971 | North America | Isolation or structure | Wani and colleagues report the isolation and structure of taxol from Taxus brevifolia. | Wani et al. 1971 |
| 1972 | China | Isolation or structure | Artemisinin isolated in November 1972; the extract was first tested in 30 patients from August to October 1972. | Tu 2015 |
| 1977–1998 | North America | Historical record | Moerman's ethnobotany database: 4,869 items (1977), 17,634 medicinal items (1986), 44,691 uses by 291 groups (1998 book). | BRIT, Native American Ethnobotany Database |
| 1983 | North America | Clinical use or approval | FDA approves etoposide (VePesid), a semi-synthetic derivative of mayapple podophyllotoxin, November 10, 1983. | Drugs@FDA, NDA 018768 |
| 1986 | China | Clinical use or approval | Artemisinin receives new-drug approval in China; dihydroartemisinin follows in 1992. | Tu 2015 |
| 1987 | Japan | Law, policy or agreement | 148 Kampo formulas covered by National Health Insurance by 1987, the number still listed. | Kwon et al. 2026; Uneda et al. 2024 |
| 1992 | North America | Clinical use or approval | FDA approves Taxol (paclitaxel), December 29, 1992. | Drugs@FDA, NDA 020262 |
| 1992–1993 | International law | Law, policy or agreement | Convention on Biological Diversity opens for signature (June 5, 1992) and enters into force (December 29, 1993). The United States signed but is not a Party. | CBD Secretariat |
| 1995 | Africa | Law, policy or agreement | CSIR patents P57 from Hoodia; a licence goes to Phytopharm six years later. | Reihling 2008 |
| 2001 | Europe | Clinical use or approval | FDA approves galantamine, a snowdrop alkaloid earlier used in Eastern Europe, February 28, 2001. | Heinrich and Teoh 2004; Drugs@FDA, NDA 021169 |
| 2003 | Africa | Law, policy or agreement | Benefit-sharing agreement gives the San a 6% share of CSIR's financial benefits from its partners. | Reihling 2008 |
| 2003 and 2005 | Africa | Law, policy or agreement | Patents on Pelargonium sidoides and P. reniforme extracts granted 2003 and 2005 with no benefit-sharing agreement, per the African Centre for Biosafety. | Reihling 2008 |
| 2009 | China | Clinical use or approval | FDA approves Coartem (artemether–lumefantrine), April 7, 2009. | Drugs@FDA, NDA 022268 |
| 2010 | International law | Law, policy or agreement | Nagoya Protocol on access and benefit-sharing adopted, October 29, 2010. | CBD Secretariat |
| 2014 | International law | Law, policy or agreement | Nagoya Protocol enters into force, October 12, 2014; 143 Parties as of October 2026, not including the United States. | CBD Secretariat |
| 2019 | International law | Law, policy or agreement | WHO reports that 170 Member States acknowledge use of traditional and complementary medicine. | WHO 2019 |
| 2024 | International law | Law, policy or agreement | WIPO treaty adopted May 24, 2024: patent applicants must disclose the origin of genetic resources and associated traditional knowledge. | WIPO |
No dated step matches this combination. Try another era or region.
Explanation, details and sources
Twelve lanes run from 2500 BCE to 2030, with the axis stretched after 1500 CE. The explorer filters the same 65 dated steps by region, era and kind, and highlights the region on the atlas.
Clay tablets and papyri recorded hundreds of prescriptions, yet most of their ingredients cannot be identified today
Show data: Ebers Papyrus contents
| Area of medicine | Numbered prescriptions | Count |
|---|---|---|
| Spells to be chanted before treatment | Eb 1–6 | 6 |
| Internal medicine | Eb 7–335 | 329 |
| Eye disorders | Eb 336–431 | 96 |
| Skin disorders | Eb 432–602 | 171 |
| Diseases of the extremities | Eb 603–696 | 94 |
| Miscellaneous: head, tongue, teeth, nose, ears, cosmetics | Eb 697–782 | 86 |
| Gynaecology | Eb 783–853 | 71 |
| Information about the cardiovascular system | Eb 854–856 | 3 |
| Ulcers | Eb 857–877 | 21 |
| Type of text | Count |
|---|---|
| Abridged prescriptions | 776 |
| Teaching texts | 44 |
| Prescriptions with remnants of the teaching text | 28 |
| Prescriptions with additional magic | 11 |
| Magic texts with medical applications | 10 |
| Prognoses | 4 |
| Compilations of teaching texts | 4 |
| Magic text without medical application | 1 |
Counts are the library's numbered ranges and categories. Leipzig University Library, Papyrus Ebers. The scroll's date (end of the 16th century BCE) rests on the calendar on its reverse and radiocarbon dating performed in 2014.
Explanation, details and sources
Mesopotamian healers wrote prescriptions on clay by about 2200 BCE, and the Nineveh encyclopaedia of the 7th century BCE ran to more than 10,000 lines. The Ebers Papyrus holds 879 texts, and the library that owns it notes that 70–80% of their ingredients have not been identified.
Check dates against the holding institution. A widely cited 2012 review dates the Ebers Papyrus to 2900 BCE; the library dates it to the end of the 16th century BCE from the calendar on its reverse and radiocarbon dating.
Chinese materia medica grew five-fold over fifteen centuries, and Japan reimburses 148 Kampo formulas today
Show data: Chinese bencao and Kampo milestones
| Work | Date | Medicinals | Note |
|---|---|---|---|
| Shennong Bencao Jing | Eastern Han, 25–220 CE | 365 | Earliest extant bencao; three grades |
| Bencao Jing Jizhu (Tao Hongjing) | 420–589 | 730 | Adds 365 entries |
| Xin Xiu Bencao | 659 | 850 | Described as China's earliest national pharmacopoeia |
| Zheng Lei Bencao | 1108 | 1,746 | Described as the only Song or earlier bencao to survive intact |
| Bencao Gangmu (Li Shizhen) | Completed 1578; printed 1593–1596 | 1,892 | 11,096 prescriptions; 1,109 illustrations in the 1593 printing |
Japan: medical books on herbal drugs and acupuncture arrived from Wu in 562; exchange with China stopped in 894; Tamba Yasuyori presented the Ishinpō, the oldest extant medical book in Japan, to the emperor in 984. Kampo formulas were first covered by national health insurance in 1967, coverage expanded from 1976, and 148 formulas were covered by 1987, the number still listed.
Explanation, details and sources
Each major bencao (materia medica, a catalogue of medicinal substances) preserved and extended its predecessors, from 365 medicinals in the Eastern Han to 1,892 in Li Shizhen's Bencao Gangmu. Japan received Chinese medical books in 562, and its national health insurance has covered Kampo formulas since 1967.
Artemisinin came from screening more than 2,000 prescriptions and changing one extraction step
The record supplied a candidate and a clue. Identity, chemistry and trials supplied the medicine: of at least six Artemisia species, only A. annua contains meaningful artemisinin.
Text version of the worked example
- 1969: Tu Youyou gathered over 2,000 herbal, animal and mineral prescriptions in three months and kept 640 in a brochure circulated in April 1969.
- May 1969 to June 1971: water and ethanol extracts of over 100 herbs were tested in rodent malaria, with few promising results.
- 1971: the team focused on qinghao. Ge Hong's handbook (East Jin dynasty, about 317–420) first records qinghao for periodic fevers; it led to a lower extraction temperature.
- September 1971: extraction with ethyl ether at reduced temperature; an alkaline wash removed the acidic portion.
- October 4, 1971: sample 191, the neutral portion, was fully effective in rodent malaria; monkey tests followed from December 1971 to January 1972.
- August to October 1972: the extract was tested in 30 patients, 21 in Hainan and 9 in Beijing. Silica-gel separation followed, and artemisinin was isolated in November 1972.
- April 27, 1973: the formula C15H22O5 was established; the X-ray stereostructure was published in 1977.
- Approvals: artemisinin in China in 1986, dihydroartemisinin in 1992; FDA approved Coartem (artemether–lumefantrine) in 2009. In 2015 Tu Youyou received one half of the Nobel Prize in Physiology or Medicine "for her discoveries concerning a novel therapy against Malaria".
Explanation, details and sources
Tu Youyou's team tested extracts of over 100 herbs with few promising results. A 4th-century handbook by Ge Hong led them to extract qinghao with ether at a lower temperature, and sample 191 was fully effective in rodent malaria in October 1971.
Indian and Persian medical texts are well studied, but their dates and plant names still need care
Text version: dates and the reserpine story
Charaka: Britannica says he lived between the 2nd century BCE and the 2nd century CE, and estimates the Charaka-samhita in its present form at about the 1st century CE. Sushruta: Britannica says he flourished c. 6th century BCE; the Suśruta Project describes the Suśruta-samhita as composed in Sanskrit about two millennia ago.
Sarpagandha to reserpine: Sen and Bose reported Rauwolfia root for insanity and high blood pressure in 1931; Siddiqui and Siddiqui published the ajmaline series of alkaloids in 1932; Vakil's 1949 British Heart Journal paper brought Rauwolfia in hypertension to Western attention; Müller, Schlittler and Bein at CIBA isolated reserpine in pure crystalline form in 1952; the 1957 Lasker awards recognized reserpine and chlorpromazine in psychiatry, and Vakil.
Explanation, details and sources
Britannica places Charaka between the 2nd century BCE and the 2nd century CE and Sushruta in about the 6th century BCE; the Suśruta Project dates that text to about two millennia ago. In the 20th century, Indian clinicians and chemists studied sarpagandha (Rauwolfia serpentina) before CIBA chemists isolated reserpine in 1952.
Persian physicians such as al-Rāzī and Ibn Sīnā, whose Canon of Medicine devotes Book II to simple drugs, are covered as scholarship on the heritage page. U.S. sanctions (31 CFR 560.201) prohibit importing goods of Iranian origin; this course concerns texts only.
Greek and Roman texts set Europe's materia medica for about 1,400 years
Text version of the transmission
- Hippocratic Corpus, late 5th and 4th century BCE: some 60 texts by several authors; pharmakon usually meant a purgative.
- Theophrastus (c. 371–287 BCE), Aristotle's pupil: Inquiry into Plants in nine books and Growth of Plants in six.
- Dioscorides, De materia medica, about 77 CE: five books, nearly 600 plants, about 1,000 simple drugs. Pliny the Elder (23–79 CE) wrote the Natural History in 37 books.
- Galen of Pergamum (129–c. 216): dominant in European medicine until the mid-17th century; his authority was similarly long-lived in the Byzantine world and the Muslim Middle East.
- Vienna Dioscurides, early 6th century: an illustrated copy made for Juliana Anicia, restored in 1406, inscribed in the Memory of the World Register in 1997.
- al-Rāzī (c. 854/865–925) and Ibn Sīnā, whose Canon was begun about 1012; Gerard of Cremona translated the Canon into Latin in Toledo in the 12th century; the Articella was taught at Salerno, Montpellier, Bologna and Paris up to the 17th century, and an Arabic Canon was printed in Rome in 1593.
Explanation, details and sources
The Hippocratic Corpus, some 60 texts by several authors, mostly used pharmakon for a purgative. Dioscorides' De materia medica (about 77 CE) described nearly 600 plants and served as the primary text of pharmacology until the end of the 15th century.
In Africa, an ordeal poison became an eye drug, and a reputed diabetes remedy led to cancer drugs
Text version of the African cases
- Calabar bean (Physostigma venenosum): missionaries who arrived in Old Calabar in 1846 documented the ordeal bean; Christison tested a bean on himself in 1855; Balfour named the plant about six years later; Argyll Robertson showed in 1863 that the extract constricts the pupil. Physostigmine was isolated in 1864, its structure was known by 1923, and it has been used for glaucoma and myasthenia gravis.
- Madagascar periwinkle (Catharanthus roseus): leaf extracts were reputed to help in diabetes. Testing that claim, Noble and Beer found the anticancer alkaloids vinblastine and vincristine in the 1950s.
- Pelargonium sidoides: a Southern African traditional medicine sold in Europe as Stevens' Cure and later Umckaloabo, with 18 clinical studies by 2008, mainly in acute bronchitis. Patents on extracts of P. sidoides and P. reniforme were granted in 2003 and 2005 without a benefit-sharing agreement, according to the African Centre for Biosafety.
- Hoodia gordonii: also used by the Khoisan. CSIR patented P57 in 1995 and licensed it six years later; a 2003 agreement gives the San a 6% share of CSIR's financial benefits from its partners. A 15-day trial of a purified extract found no effect on energy intake or body weight.
Explanation, details and sources
Missionaries documented the Calabar ordeal bean in 1846; physostigmine was isolated from it in 1864. Testing a folk antidiabetic use of Madagascar periwinkle led Noble and Beer to vinblastine and vincristine in the 1950s. The Pelargonium and Hoodia cases show why benefit-sharing law followed.
South American plants gave quinine, tubocurarine and pilocarpine, and a 44,691-record database documents North American plant uses
Text version of the South American cases
- Cinchona bark: Jesuit missionaries in South America used it against fevers about 1630, and a legend credits earlier Indigenous use. Pelletier and Caventou isolated and named quinine in 1820, and purified quinine replaced the bark. Achan and colleagues describe quinine as the first successful use of a chemical compound against an infectious disease.
- Curare: explorers described South American arrow poisons in the 16th century; Claude Bernard located their site of action in the mid-19th century; King isolated tubocurarine in 1935; neuromuscular blockers became established as muscle relaxants in surgery after 1943.
- Jaborandi (Pilocarpus): Symphronio Coutinho took the leaves to Europe in 1873; Hardy and Gerrard independently discovered pilocarpine in 1875; Weber introduced it as a pupil-constricting eye drug in 1876.
Show data: database records by use and by group
| Group, as named in the database | Records | Drug | Food | Other | Fiber | Dye |
|---|---|---|---|---|---|---|
| Cherokee | 3,313 | 2,715 (82%) | 309 | 153 | 108 | 28 |
| Iroquois | 2,994 | 2,505 (84%) | 424 | 45 | 14 | 6 |
| Thompson | 1,979 | 1,067 (54%) | 493 | 258 | 144 | 17 |
| Navajo, Ramah | 1,382 | 1,027 (74%) | 166 | 124 | 45 | 20 |
| Paiute | 1,187 | 871 (73%) | 217 | 69 | 29 | 1 |
| Okanagan-Colville | 975 | 520 (53%) | 185 | 189 | 72 | 9 |
| Navajo | 973 | 293 (30%) | 322 | 244 | 52 | 62 |
| Blackfoot | 964 | 546 (57%) | 161 | 209 | 25 | 23 |
| Seminole | 827 | 643 (78%) | 61 | 106 | 14 | 3 |
| Shoshoni | 815 | 777 (95%) | 13 | 11 | 9 | 5 |
| Ojibwa | 814 | 437 (54%) | 190 | 88 | 76 | 23 |
| Hopi | 807 | 263 (33%) | 238 | 229 | 44 | 33 |
| All 291 groups | 44,691 | 24,945 | 11,078 | 5,494 | 2,567 | 607 |
Mayapple (Podophyllum peltatum): 39 records from Iroquois (13), Cherokee (12), Meskwaki (5), Delaware, Oklahoma (3), Menominee (3), Delaware (2) and Chippewa (1); 25 drug, 11 food and 3 other records. Earlier editions: 4,869 items (1977) and 17,634 medicinal items from 123 groups (1986).
Explanation, details and sources
Quinine was isolated from cinchona bark in 1820, tubocurarine from curare in 1935 and pilocarpine from jaborandi in 1875. For jaborandi, scholars could not pin down any particular Indigenous use, and the name covers other plants.
Daniel Moerman's Native American Ethnobotany Database holds 44,691 records of plant uses by 291 groups, 24,945 of them drug uses. Its 39 mayapple records come from seven groups, and two record the root as poisonous; mayapple's podophyllotoxin is the starting point for etoposide.
Chemists either used the isolated compound as found or changed it into a new molecule
Text version of the two routes
- Isolated and used as found: morphine from opium poppy (Sertürner, reported 1805, full account 1817), described as the first alkaloid isolated from any plant; digoxin from woolly foxglove, Digitalis lanata (Sydney Smith, 1930), after Withering's 1785 account of the foxglove; galantamine from snowdrop, developed from Caucasian observations and Bulgarian use and approved by FDA for Alzheimer's disease on February 28, 2001.
- Chemically modified: salicin purified from willow bark (1829), then pure acetylsalicylic acid made at Bayer (1897); podophyllotoxin from mayapple, modified into etoposide (FDA, November 10, 1983), which inhibits topoisomerase II where podophyllotoxin binds tubulin; artemisinin modified into artemether, the partner of lumefantrine in Coartem (FDA, April 7, 2009).
Show data: lag from first dated report
| Drug | First dated report | Isolated | Lag (years) | First clinical use or approval | Lag (years) |
|---|---|---|---|---|---|
| Pilocarpine (jaborandi) | 1873, leaves taken to Europe | 1875 | 2 | 1876, eye drug | 3 |
| Physostigmine (Calabar bean) | 1846, ordeal use documented | 1864 | 18 | not dated here | – |
| Reserpine (Rauwolfia) | 1931, Indian clinical report | 1952 | 21 | not dated here | – |
| Salicin, then aspirin (willow) | 1763, Stone's report | 1829 | 66 | 1897, aspirin | 134 |
| Digoxin (foxglove) | 1785, Withering's account | 1930 | 145 | not dated here | – |
| Etoposide (mayapple) | 1820, first U.S. Pharmacopoeia | not dated here | – | 1983, FDA approval | 163 |
| Quinine (cinchona) | c. 1630, Jesuits' use | 1820 | 190 | not dated here | – |
| Tubocurarine (curare) | 16th century, explorers' reports | 1935 | 336–435 | after 1943, surgical use | 344–443 |
| Artemisinin (qinghao) | c. 317–420, Ge Hong's handbook | 1972 | 1,552–1,655 | 1986, approval in China | 1,566–1,669 |
Explanation, details and sources
Morphine, digoxin and galantamine are used much as they were isolated. Aspirin, etoposide and artemether are modified molecules, and etoposide acts on a different target from its parent podophyllotoxin.
Δt is the lag in years; tfirst report is the first dated report of the plant's use in the sources cited, which is never the first use. A range appears where that report is dated only to a period.
Natural products and their derivatives remain a large share of new drugs, especially for cancer
Show data: Newman and Cragg 2020
| Set | Category | Count | Share |
|---|---|---|---|
| Anticancer small molecules, 1946–1980 (75) | N or ND | 40 | 53.3% |
| Anticancer small molecules, 1981–2019 (185) | N* (natural product or derivative) | 62 | 33.5% |
| Anticancer small molecules, 1981–2019 (185) | S* and S*/NM (synthetic, natural-product pharmacophore) | 58 | 31.4% |
| Anticancer small molecules, 1981–2019 (185) | N*, S* and S*/NM together | 120 | 64.9% |
| All new drugs, 1981–2019 (1,881) | N, unaltered natural product | – | 3.8% |
| All new drugs, 1981–2019 (1,881) | NB, botanical defined mixture | – | 0.8% |
| All new drugs, 1981–2019 (1,881) | ND, natural-product derivative | – | 18.9% |
The 31.4% share of S* and S*/NM is computed here from the abstract's counts (58 of 185). The NB share is as reproduced in Sarbadhikary P, George BP. Plants 2022;11:2293.
Explanation, details and sources
Newman and Cragg classify every drug approved worldwide by origin. Of 185 anticancer small molecules approved from 1981 to September 2019, 62 were natural products or derivatives and 58 were synthetics built on a natural-product pharmacophore (the part of a molecule that produces its action): 64.9% together.
Across all 1,881 approvals, unaltered natural products were 3.8% and botanical defined mixtures 0.8%. Many natural-product drugs come from microbes, so these shares do not measure what traditional plant knowledge contributed.
A historical record is a hypothesis that must pass six gates before it becomes a medicine
Text version of the ten cases
- Passed all four (recorded use, compound isolated, medicine, matching use): qinghao to artemisinin, cinchona to quinine, willow to aspirin.
- Medicine with a different use from the tradition: Calabar bean to physostigmine (recorded as an ordeal poison), periwinkle to vinca alkaloids (tested as antidiabetic, anticancer activity found).
- Medicine without a clear traditional use: jaborandi to pilocarpine (Indigenous use could not be pinned down), Pacific yew to paclitaxel (found by plant screening).
- Medicine from a related synthetic: goat's rue to metformin (guanidine lowered blood glucose in 1918; metformin is synthetic).
- No medicine: Hoodia (a 15-day trial of a purified extract found no effect on energy intake or body weight) and Aristolochia (aristolochic acids are listed as known human carcinogens).
- Centuries of use≠demonstrated safety
- A traditional claim≠the activity later found
- A historical plant name≠a verified species
Explanation, details and sources
Three of these ten cases pass all four questions. In the others the medicine came from a different activity, from screening, or not at all, and Aristolochia caused documented harm.
170 WHO Member States report traditional-medicine use, and regulation of herbal medicines varies widely by region
Show data: Member States with each indicator as at 2018
| Indicator | Africa (47) | Americas (35) | Eastern Mediterranean (21) | Europe (53) | South-East Asia (11) | Western Pacific (27) | All (194) |
|---|---|---|---|---|---|---|---|
| Population uses T&CM | 41 (87%) | 28 (80%) | 19 (90%) | 47 (89%) | 10 (91%) | 25 (93%) | 88% |
| National policy on T&CM | 40 (85%) | 11 (31%) | 9 (43%) | 11 (21%) | 10 (91%) | 17 (63%) | 51% |
| Laws or regulations on T&CM | 39 (83%) | 15 (43%) | 12 (57%) | 21 (40%) | 9 (82%) | 13 (48%) | 56% |
| National programme on T&CM | 34 (72%) | 13 (37%) | 4 (19%) | 7 (13%) | 10 (91%) | 11 (41%) | 41% |
| National office for T&CM | 39 (83%) | 17 (49%) | 13 (62%) | 15 (28%) | 10 (91%) | 13 (48%) | 55% |
| Expert committee on T&CM | 34 (72%) | 12 (34%) | 11 (52%) | 15 (28%) | 10 (91%) | 11 (41%) | 48% |
| National research institute | 29 (62%) | 9 (26%) | 10 (48%) | 11 (21%) | 7 (64%) | 9 (33%) | 39% |
| Regulation of herbal medicines | 20 (43%) | 18 (51%) | 18 (86%) | 45 (85%) | 10 (91%) | 13 (48%) | 64% |
| Registration of herbal medicines | 23 (49%) | 19 (54%) | 17 (81%) | 45 (85%) | 10 (91%) | 11 (41%) | 64% |
Explanation, details and sources
WHO's 2019 global report, with information from 179 Member States, found that 88% acknowledge use of traditional and complementary medicine (T&CM). The European Region regulates herbal medicines in 85% of its states but has a national T&CM policy in 21%; the African Region shows the reverse.
Traditional knowledge now carries legal obligations under treaties the United States has not joined
This course follows the same rules: it cites recorded scholarship by name and gives no preparation or dosing instructions for any traditional remedy.
Text version of the timeline
- June 5, 1992: the Convention on Biological Diversity opens for signature at Rio. June 4, 1993: the United States signs; it has not become a Party. December 29, 1993: the Convention enters into force.
- 1995: CSIR patents P57 from Hoodia; 2001: licence to Phytopharm; 2003: benefit-sharing agreement with the San. 2003 and 2005: patents on Pelargonium extracts, with no benefit-sharing agreement according to the African Centre for Biosafety.
- October 29, 2010: the Nagoya Protocol is adopted; October 12, 2014: it enters into force; October 2026: 143 Parties.
- May 24, 2024: WIPO adopts a treaty requiring patent applicants to disclose the country of origin of genetic resources, or the Indigenous Peoples or local community that provided associated traditional knowledge, when a claimed invention is based on them.
Explanation, details and sources
The Convention on Biological Diversity entered into force in 1993 and its Nagoya Protocol in 2014; the Protocol has 143 Parties as of October 2026. The United States signed the Convention but is a Party to neither, and provider countries' access laws can still apply to material collected there.
Eleven terms used in this course
Show the 11 key terms
- Materia medica
- A text listing medicinal substances, their sources and uses; bencao in Chinese.
- Hippocratic Corpus
- About 60 Greek medical texts by several authors, mostly 5th–4th century BCE.
- Kampo
- Japanese medicine adapted from Chinese sources; 148 formulas are reimbursed.
- Ethnobotany
- The study of how people use plants, from interviews, observation and texts.
- Alkaloid
- A basic, nitrogen-containing plant compound, such as morphine or quinine.
- Isolation
- Obtaining one compound in pure form from an extract.
- Semi-synthetic derivative
- A natural product changed chemically, as etoposide from podophyllotoxin.
- N, NB and ND
- Newman and Cragg's codes for natural product, botanical mixture and derivative.
- T&CM
- Traditional and complementary medicine, WHO's term.
- Access and benefit-sharing
- Using genetic resources or traditional knowledge with consent, and sharing the benefits.
- Nagoya Protocol
- The 2010 benefit-sharing agreement under the Convention on Biological Diversity.
Five questions on reading the historical record
Why can most remedies in the Ebers Papyrus not be reconstructed today?
The text survives, but the holding library notes that 70–80% of its ingredients have not been identified. Without the species and plant part, a prescription cannot be prepared or tested.
Ge Hong's handbook did not contain artemisinin. What did it contribute?
A candidate plant and a clue about method. It led Tu Youyou's team to a lower extraction temperature. Species identity, isolation, structure work and trials produced the medicine.
What does the periwinkle story show about traditional claims?
The reputed antidiabetic use was the reason for testing, but the result was anticancer alkaloids. A traditional claim is a hypothesis; testing can reveal a different activity or none.
Why do two Navajo entries in the ethnobotany database show 30% and 74% drug records?
The database counts published records, and the two entries come from different sources. Shares reflect what each source studied and asked, as well as what each community used.
Does the 64.9% figure for anticancer drugs show that traditional plant knowledge produced most cancer drugs?
No. It counts natural products, derivatives and synthetics built on a natural pharmacophore, many from microbes and from screening, such as paclitaxel. It says nothing about traditional use.
Next: the botanicals regulation has left untested
Course 2 follows the funnel from all plant species to the few with full evidence, and the barriers in between.